Thyroid Nodule Evaluation and Management Guidelines

Initial Assessment

• Begin evaluation of any thyroid nodule with serum TSH measurement and high‑resolution ultrasound; apply the EU‑TIRADS classification to decide whether fine‑needle aspiration biopsy (FNAB) is needed and then manage according to Bethesda cytology results. 1
• When TSH < 0.4 mIU/L, perform thyroid scintigraphy (99mTc or 123I) to identify autonomous (“hot”) nodules. 1, 2
• Autonomous (hot) nodules have an extremely low risk of malignancy and therefore rarely require FNAB. 1
• Overt or symptomatic subclinical hyperthyroidism should be treated first‑line with radioactive iodine (RAI). 1
• Surgery for autonomous nodules is reserved for compressive symptoms, planned pregnancy within 6 months, or patient preference. 1
• If TSH is normal or elevated, proceed directly to ultrasound risk stratification using EU‑TIRADS. 1

EU‑TIRADS Risk Stratification

• EU‑TIRADS assigns malignancy risk based on specific ultrasound features; high‑risk features include marked hypoechogenicity (relative to muscle), taller‑than‑wide shape, microcalcifications, and irregular margins. 1

FNAB Indication Algorithm

All recommendations are based on EU‑TIRADS score combined with nodule size. 1

Cytology‑Based Management (Bethesda System)

Bethesda I – Non‑diagnostic

• Repeat FNAB under ultrasound guidance for nodules > 10 mm classified as EU‑TIRADS 3‑5. 1
• If the second FNAB remains non‑diagnostic, consider a core‑needle biopsy. 1
• Persistent non‑diagnosis warrants discussion of surgical removal, taking nodule size and clinical context into account. 1

Bethesda II – Benign

• Routine repeat FNAB is not required for benign cytology. 1, 2
• EU‑TIRADS 5 nodules with benign cytology should be monitored with ultrasound every 1–2 years for the first 5 years, then at longer intervals if stable. 1
• Repeat FNAB is indicated only if:
  
  • Multiple high‑risk ultrasound features are present (marked hypoechogenicity, taller‑than‑wide shape, microcalcifications, irregular margins), or
  • There is a significant increase in nodule size or new suspicious ultrasound changes. 1, 2

Bethesda III–IV – Indeterminate

• For nodules > 15 mm that are not hot on scintigraphy, 99mTc‑MIBI scintigraphy can be used because of its high negative predictive value. 2
• An alternative approach is to repeat FNAB. 1

Bethesda V–VI – Suspicious/Malignant

• Proceed to surgical evaluation; the extent of surgery is guided by tumor characteristics, risk stratification, and patient factors. (Guideline statement without a specific citation; omitted per instructions.)

Post‑Procedural Surveillance

After Lobectomy for Benign Nodules

• Measure serum TSH at 6–8 weeks post‑operatively. 1

After Lobectomy for Low/Intermediate‑Risk Cancer

• Measure serum TSH at 6–8 weeks post‑operatively.
• Initiate levothyroxine replacement if TSH > 2 mIU/L in the absence of residual disease.
• Conduct cervical ultrasound surveillance at 6–12 months, 3 years, 5 years, and then every 5 years. 1

Management of Autonomous (Hot) Nodules

• Prior to RAI therapy, consider beta‑blockers and antithyroid drugs for patients with cardiovascular risk or markedly elevated FT3. 1
• If antithyroid drugs are used, prefer imidazoles, maintain TSH suppression, and discontinue the drug 5–7 days before RAI administration. 1
• Apply the ALARA principle by using the lowest effective radioiodine activity. 1
• Post‑RAI monitoring of TSH should be performed at 1, 3, 6, 12 months and annually thereafter to detect late hypothyroidism. 1

Critical Pitfalls to Avoid

• Do not biopsy hot nodules identified on scintigraphy; their malignancy risk is essentially negligible. 1
• Do not automatically repeat FNAB for all Bethesda II nodules; repeat only when high‑risk ultrasound features or significant growth are present. 1, 2